Cardiovascular Drugs: Global Markets to 2022

  • ID: 4480536
  • Report
  • Region: Global
  • 174 Pages
  • BCC Research
1 of 5
The Report Includes an Industrywide Assessment of the Novel Product Launches, Recent Approvals, Research and Development Pipeline, and Blockbuster Drugs

FEATURED COMPANIES

  • Amgen Inc.
  • Astrazeneca PLC
  • Eli Lilly and Company
  • Glaxosmithkline PLC
  • Johnson & Johnson Inc.
  • Novartis AG
  • MORE

Report Scope:

This report provides detailed exposure of the cardiovascular drugs market, highlighting major cardiovascular diseases with detailed epidemiology for the primary disease areas. The report includes an industrywide assessment of the novel product launches, recent approvals, research and development pipeline, and blockbuster drugs.

Strict regulations are imposed on cardiovascular drugs and the report discusses the regional regulatory landscape for these drugs. This includes products approved by the regulatory authorities in recent years. Products under development or that are in different stages of clinical trials are analyzed in the pipeline assessment section.

Cardiovascular drug delivery systems are also included in the report, such as nanoparticle-mediated drug delivery, gene therapy and cell therapy, among others.

A discussion of the major players is included in the competitive landscape section, which looks at trends in product launches, collaborations, mergers and acquisitions, and other agreements. Company profiles of major players operating in the cardiovascular drugs market include overviews, key product offerings, financials, strategies, SWOT analysis, and new research and development strategies. The report will be particularly useful to readers in its thorough analysis of the leading products and will enable readers to recognize growing brands, key drug classes, and leading manufacturing companies with significant market share.

Report Includes:

  • 52 data tables and 48 additional tables
  • An overview of the global market for cardiovascular drugs
  • Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • A look at the regulatory environment, which has been a driving force in drug development
  • Information on competitor initiatives, and information with regard to demand for specialty chemicals used to develop new products and for new applications
  • Company profiles of the major players in the market, including Daiichi Sankyo Company Ltd., Johnson & Johnson, Novartis AG, AstraZeneca PLC, United Therapeutics Corp., Gilead Sciences Inc. and Pfizer Inc
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Astrazeneca PLC
  • Eli Lilly and Company
  • Glaxosmithkline PLC
  • Johnson & Johnson Inc.
  • Novartis AG
  • MORE

1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials

2 Summary and Highlights

3 Market Dynamics and Technology Background

  • Cardiovascular Drugs Market Definition and Overview
  • Epidemiology of Cardiovascular Diseases
  • Blockbuster Drugs
  • Market Drivers
  • Emergence of Effective Therapies for Hypertension and Hyperlipidemia
  • Increase in Aging Population
  • Government Regulations Improving Prescription Drug Assistance for the Elderly
  • Prevalence of Comorbidities Such as Diabetes and Obesity
  • Market Restraints
  • Lack of Incentives to Promote Cardiovascular Drug Development
  • Pricing Pressure Enforced on Manufacturers
  • High Cost Associated with New Drug Development and Clinical Trials
  • Patent Expiration of Blockbuster Drugs Leading to Wide Adoption of Generics
  • Market Opportunities
  • Focus on Prevention of Cardiovascular Disease
  • Emergence of Combination Therapy

4 Pipeline Analysis

  • Research and Development Overview
  • Current Scenario of Cardiovascular Investments for Research and Development
  • Novel Drug Development/Approval
  • Promising Pipeline Molecules/Drugs in Development

5 Regulatory Scenario

  • Introduction
  • Regional Regulatory Landscape
  • North America
  • Europe
  • Asia-Pacific
  • Cardiovascular Drugs Approved

6 Cardiovascular Drug Delivery Systems

  • Introduction
  • Iontophoresis
  • Nanoparticle-Mediated Drug Delivery
  • Pericardiocentesis
  • Intracoronary Drug Delivery
  • Gene Therapy
  • Future Perspectives

7 Market Breakdown by Disease Areas

  • Disease Type
  • Hypertension
  • Hyperlipidemia
  • Thrombosis
  • Cardiac Failure Therapy
  • Stroke
  • Arrhythmias
  • Myocardial Infarction
  • Heart Failure
  • Acute Coronary Syndrome
  • Other Cardiovascular Diseases
  • Pulmonary Hypertension
  • Peripheral Artery Diseases
  • Inflammatory Heart Disease
  • Other Diseases

8 Market Breakdown by Drug Class

  • Introduction
  • Alpha-Blockers
  • Anti-Thrombotic (Anti-Coagulants and Anti-Platelets)
  • Lipid Lowering Agents
  • Anti-Hypertensives
  • Anti-Arrhythmic Drugs
  • Others

9 Market Breakdown by Region

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • Rest of Asia Pacific
  • Middle East and Africa
  • South America

10 Competitive Landscape and Key Developments

  • Major Players and Market Structure Analysis
  • Key Developments
  • Mergers and Acquisitions
  • New Product Launch
  • Agreement, Collaboration and Partnerships

11 Company Profiles

  • Amgen Inc.
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Astellas Pharma Inc.
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Astrazeneca Plc
  • Company Overview
  • Financials
  • Product Information
  • Brilinta R (ticagrelor) tablets:
  • Crestor:
  • Development and Strategies
  • Boehringer Ingelheim GMBH
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Bristol-Myers Squibb Company
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Daiichi Sankyo Company LTD.
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Eli Lilly and Company
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Gilead Sciences Inc.
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Glaxosmithkline PLC
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Hikma Pharmaceuticals PLC
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Johnson & Johnson Inc.
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Product Information
  • Merck & Co. Inc.
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Novartis AG
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Pfizer Inc.
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • Sanofi
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • United Therapeutics Corp.
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies

12 Appendix

  • Acronyms

List of Tables
Summary Table A : Global Market for Cardiovascular Drugs, by Disease Area, Through 2022
Summary Table B : Global Market for Cardiovascular Drugs, by Drug Class, Through 2022
Summary Table C : Global Market for Cardiovascular Drugs, by Region, Through 2022
Table 1 : Prevalence of High Blood Pressure, Age 18+, 2015
Table 2 : List of Blockbuster Drugs, Manufacturer, 2014-2016
Table 3 : Life Expectancy at Birth, Both Sexes Combined, by Region, 1990-2030
Table 4 : Prevalence Rates for Adult Obesity, by Country, 2016
Table 5 : Prevalence Rates of Australia Obesity for Male and Female, 1995-2015
Table 6 : Cardiovascular Drugs Affected by the New Drug Price Control, Brand Name, Generic Name, Manufacturer
Table 7 : Cardiovascular Drugs Going Off-Patent, 2016-2021
Table 8 : Giapreza Snapshot
Table 9 : Uptravi Snapshot
Table 10 : Invokana Snapshot
Table 11 : Praluent Development Timeline
Table 12 : Omecamtiv Mecarbil Developmental Pipeline
Table 13 : AstraZeneca Plc. Cardiovascular Pipeline
Table 14 : Amgen Inc. Cardiovascular Pipeline
Table 15 : Pfizer Inc. Cardiovascular Pipeline
Table 16 : Sanofi Cardiovascular Pipeline
Table 17 : Novartis AG Cardiovascular Pipeline
Table 18 : Merck and Co. Inc. Cardiovascular Pipeline
Table 19 : Daiichi Sankyo Company, Ltd. Cardiovascular Pipeline
Table 20 : Bristol-Myers Squibb Company Cardiovascular Pipeline
Table 21 : Gilead Sciences Inc. Cardiovascular Pipeline
Table 22 : Indicative List of Cardiovascular Drugs Approved by U.S. FDA and Health Canada (Brand Name, Manufacturer, Indication, Approval Date, and Approving Agency), 2015-2017
Table 23 : Indicative List of Cardiovascular Drugs Approved by EMA (Brand Name, Manufacturer, Indication, and Approval Date), 2011-2016
Table 24 : Cardiovascular Drugs Approved by PMDA (Brand Name, Manufacturer, Indication, and Approval Date), 2016-2017
Table 25 : Indicative List of Cardiovascular Drugs Approved, U.S. FDA, EMA and DCGI (Generic Name, Indication, Approval Year), 2006-2011
Table 26 : Cardiovascular Drugs Approved (Brand Name, Generic Name, Approval Year, Manufacturer, and Indication), 2011-2016
Table 27 : Global Cardiovascular Drugs Market, by Disease Area, Through 2022
Table 28 : Classification of Hypertension or Blood Pressure
Table 29 : Global Hypertension Market, by Region, Through 2022
Table 30 : Recommended Cholesterol Levels
Table 31 : Global Hyperlipidemia Market, by Region, Through 2022
Table 32 : Global Thrombosis Market, by Region, Through 2022
Table 33 : Global Cardiac Failure Therapy Market, by Region, Through 2022
Table 34 : New York Heart Association Classification
Table 35 : American Heart Association Classification
Table 36 : Global Market for Other Cardiovascular Drugs, by Region, Through 2022
Table 37 : Global Alpha-Blockers Market, by Region, Through 2022
Table 38 : Global Anti-Thrombotic Market, by Region, Through 2022
Table 39 : Global Lipid Lowering Agents Market, by Region, Through 2022
Table 40 : Global Anti-Hypertensives Market, by Region, Through 2022
Table 41 : Global Anti-Arrhythmic Drugs Market, by Region, Through 2022
Table 42 : Global Anti-Arrhythmic Drug Classification, by Vaughan Williams Classification
Table 43 : Global Market for Other Cardiovascular Drugs, by Region, Through 2022
Table 44 : Global North American Cardiovascular Drugs Market, by Country, Through 2022
Table 45 : European Cardiovascular Drugs Market, by Country, Through 2022
Table 46 : Asia-Pacific Cardiovascular Drugs Market, by Country, Through 2022
Table 47 : Global Cardiovascular Companies Ranking
Table 48 : Patent Review, 2016-2017
Table 49 : Repatha Snapshot
Table 50 : Jardiance Snapshot
Table 51 : Industry-wide Collaborations
Table 52 : Amgen Net Revenue, 2015-2017
Table 53 : Amgen Inc., Marketed Products, 2016
Table 54 : Astellas Pharma Inc. Net Revenue, 2015-2017
Table 55 : Astellas Pharma Inc. Marketed Products, 2017
Table 56 : AstraZeneca PLC Net Revenue, 2014-2016
Table 57 : AstraZeneca PLC Marketed Products, 2016
Table 58 : AstraZeneca Global Cardiovascular Product Sales, 2014-2016
Table 59 : Boehringer Ingelheim GmbH Net Revenue, 2014-2016
Table 60 : Boehringer Ingelheim Marketed Products, by Indication, 2016
Table 61 : Boehringer Ingelheim GmbH Global Cardiovascular Product Sales, 2014-2016
Table 62 : Bristol-Myers Squibb Company Net Revenue, 2014-2016
Table 63 : Bristol-Myers Squibb Company Marketed Products, 2016
Table 64 : Daiichi Sankyo Company Ltd. Net Revenue, 2015-2017
Table 65 : Daiichi Sankyo Company Ltd. Marketed Products, by Indication, 2016
Table 66 : Eli Lilly and Company Net Revenue, 2014-2016
Table 67 : Eli Lilly and Company Marketed Products
Table 68 : Gilead Sciences Inc. Net Revenue, 2014-2016
Table 69 : Gilead Science Inc. Marketed Products
Table 70 : GlaxoSmithKline PLC Net Revenue, 2014-2016
Table 71 : GlaxoSmithKline PLC Marketed Products
Table 72 : Hikma Pharmaceuticals PLC Net Revenue, 2014-2016
Table 73 : Hikma Pharmaceuticals PLC Marketed Products
Table 74 : Johnson & Johnson Inc. Net Revenue, 2014-2016
Table 75 : Johnson & Johnson Inc. Marketed Products, 2016
Table 76 : Johnson & Johnson Inc. Marketed Products, by Indication, 2016
Table 77 : Merck & Co. Inc. Net Revenue, 2014-2016
Table 78 : Merck & Co. Inc. Marketed Products
Table 79 : Novartis AG Net Revenue, 2014-2016
Table 80 : Novartis AG Marketed Products by Indication, 2016
Table 81 : Pfizer Inc. Net Revenue, 2014-2016
Table 82 : Pfizer Inc. Marketed Products, by Indication, 2016
Table 83 : Sanofi Net Revenue, 2014-2016
Table 84 : Sanofi Marketed Products, by Indication, 2016
Table 85 : United Therapeutics Corp. Net Revenue, 2014-2016
Table 86 : United Therapeutics Corp. Marketed Products
Table 87 : Abbreviations Used in Cardiovascular Drug Market

List of Figures
Summary Figure A : Global Market for Cardiovascular Drugs, by Disease Area, 2016-2022
Summary Figure B : Global Market for Cardiovascular Drugs, by Drug Class, 2016-2022
Summary Figure C : Global Market for Cardiovascular Drugs, by Region, 2016-2022
Figure 1 : Noncommunicable Diseases Mortality Share, by Cause of Death, 2015
Figure 2 : Top 10 Leading Causes of Death in the World, 2015
Figure 3 : Global Population Projection, Aged 60 and Above (Per 100,000 Persons)
Figure 4 : Global Population Projection, Aged 80 and Above (Per 100,000 Persons)
Figure 5 : United States Obesity, by State, 2016
Figure 6 : U.S. Generic Drug Savings, 2005-2014
Figure 7 : Likelihood of Approval from Phase I, by Disease Area
Figure 8 : The Center for Drug Evaluation and Research, by Therapeutic Area, 2017
Figure 9 : Cardiovascular Drugs Approval Process, U.S. FDA and EMEA
Figure 10 : Approved Indications for the Most Prevalent Cardiovascular Diseases, by the U.S. FDA and Health Canada, 1980-2014
Figure 11 : China CFDA Drug Regulatory Approval Process
Figure 12 : Japan PMDA Drug Regulatory Approval Process
Figure 13 : Global Cardiovascular Disease Rates for Countries with Least Age-Standardized Mortality, 2015 (Per 100,000 Persons)
Figure 14 : Global Cardiovascular Disease Rates for Countries with Highest Age-Standardized Mortality, 2015 (Per 100,000 Persons)
Figure 15 : Global Cardiovascular Drugs Market, by Disease Area, 2016-2022
Figure 16 : Global Hypertension Market, by Region, 2016-2022
Figure 17 : Global Hyperlipidemia Market, by Region, 2016-2022
Figure 18 : Global Thrombosis Market, by Region, 2016-2022
Figure 19 : Global Cardiac Failure Therapy Market, 2016-2022
Figure 20 : Global Cardiac Failure Therapy Market, by Region, 2016-2022
Figure 21 : Global Stroke Mortality, Per 100,000
Figure 22 : Global Market for Other Cardiovascular Disease, 2016-2022
Figure 23 : Global Market for Other Cardiovascular Drugs, by Region, 2016-2022
Figure 24 : Global Alpha-Blockers Market, 2016-2022
Figure 25 : Global Alpha-Blockers Market, by Region, 2016-2022
Figure 26 : Global Anti-Thrombotic Market, 2016-2022
Figure 27 : Global Anti-Thrombotic Market, by Region, 2016-2022
Figure 28 : Global Lipid Lowering Agents Market, 2016-2022
Figure 29 : Global Lipid Lowering Agents Market, by Region, 2016-2022
Figure 30 : Global Anti-Hypertensives Market, 2016-2022
Figure 31 : Global Anti-Hypertensives Market, by Region, 2016-2022
Figure 32 : Global Anti-Arrhythmic Drugs Market, 2016-2022
Figure 33 : Global Anti-Arrhythmic Drugs Market, by Region, 2016-2022
Figure 34 : Global Market for Other Cardiovascular Drugs, by Region, 2016-2022
Figure 35 : Global Cardiovascular Deaths, by Region (Per 100,000 Persons) 2015 and 2030 (F)
Figure 36 : Global North American Cardiovascular Drugs Market, 2016-2022
Figure 37 : United States’ CVD Deaths Share, 2016
Figure 38 : United States Prevalence of Cardiovascular Disease Risk Factors, % of Adults
Figure 39 : Obese (Body Mass Index >30) and Overweight (Body Mass Index >25) Population
Figure 40 : Global North American Cardiovascular Drugs Market, by Country, 2016-2022
Figure 41 : Global North American Cardiovascular Drugs Market, by Disease Area, 2016-2022
Figure 42 : Global North American Cardiovascular Drugs Market, by Drug Class, 2016-2022
Figure 43 : Global European Cardiovascular Drugs Market, 2016-2022
Figure 44 : United Kingdom Mortality in Males, 2015
Figure 45 : United Kingdom Mortality in Females, 2015
Figure 46 : Leading Causes of Death in Italy and Percent Change, 2005-2016
Figure 47 : Spain Mortality in Women, 2014
Figure 48 : Spain Mortality in Men, 2014
Figure 49 : Leading Cause of Death in Europe, 2015
Figure 50 : Global European Cardiovascular Drugs Market, by Country, 2016-2022
Figure 51 : Global European Cardiovascular Drugs Market, by Disease Area, 2016-2022
Figure 52 : Global European Cardiovascular Drugs Market, by Drug Class, 2016-2022
Figure 53 : Asia-Pacific Population Data, by Age Group, 2016
Figure 54 : Asia-Pacific Population Data, by Age Group, 2022
Figure 55 : Asia-Pacific Cardiovascular Drugs Market, 2016-2022
Figure 56 : Singapore Causes of Death, by Cardiovascular Disease Type, 2014-2016
Figure 57 : Asia-Pacific Cardiovascular Drugs Market, by Country, 2016-2022
Figure 58 : Asia-Pacific Cardiovascular Drugs Market, by Disease Area, 2016-2022
Figure 59 : Asia-Pacific Cardiovascular Drugs Market, by Drug Class, 2016-2022
Figure 60 : Cardiovascular Mortality in Middle East and Africa Region, 2017
Figure 61 : Global Middle East and Africa Cardiovascular Drugs Market, 2016-2022
Figure 62 : Global Middle East and Africa Cardiovascular Drugs Market, by Disease Area, 2016-2022
Figure 63 : Global Middle East and Africa Cardiovascular Drugs Market, by Drug Class, 2016-2022
Figure 64 : Global South American Cardiovascular Drugs Market, 2016-2022
Figure 65 : Global South American Cardiovascular Drugs Market, by Disease Area, 2016-2022
Figure 66 : Global South American Cardiovascular Drugs Market, by Drug Class, 2016-2022
Figure 67 : Amgen Inc. Revenue Share, by Region, 2017
Figure 68 : Amgen Inc. R&D Expenditure, 2014-2016
Figure 69 : Astellas Pharma Inc. Revenue Share, by Region, 2017
Figure 70 : Astellas Pharma Inc. R&D Expenditure, 2015-2017
Figure 71 : AstraZeneca PLC Revenue Share, by Region, 2016
Figure 72 : AstraZeneca PLC Revenue Share, by Business Segment, 2016
Figure 73 : AstraZeneca PLC R&D Expenditure, 2014-2016
Figure 74 : Boehringer Ingelheim GmbH Revenue Share, by Region, 2016
Figure 75 : Boehringer Ingelheim GmbH Revenue Share, by Business Segment, 2016
Figure 76 : Boehringer Ingelheim GmbH R&D Expenditure, 2014-2016
Figure 77 : Bristol-Myers Squibb Company Revenue Share, by Region, 2016
Figure 78 : Bristol-Myers Squibb Company Revenue Share, by Business Segment, 2016
Figure 79 : Daiichi Sankyo Company Revenue Share, by Business Segment, 2016
Figure 80 : Daiichi Sankyo R&D Expenditure, 2014-2016
Figure 81 : Eli Lilly and Company Revenue Share, by Business Segment, 2016
Figure 82 : Eli Lilly and Company Revenue Share, by Region, 2016
Figure 83 : Gilead Sciences Inc. Revenue Share, by Business Segment, 2016
Figure 84 : Gilead Sciences Inc. Revenue Share, by Region, 2016
Figure 85 : GlaxoSmithKline PLC Revenue Share, by Business Segment, 2016
Figure 86 : GlaxoSmithKline PLC Revenue Share, by Region, 2016
Figure 87 : Hikma Pharmaceuticals PLC Revenue Share, by Business Segment, 2016
Figure 88 : Hikma Pharmaceuticals PLC Revenue Share, by Region, 2016
Figure 89 : Johnson and Johnson Inc. Revenue Share, by Business Segment, 2016
Figure 90 : Johnson and Johnson Inc. Revenue Share, by Region, 2016
Figure 91 : Merck & Co. Inc. Revenue Share, by Business Segment, 2016
Figure 92 : Merck & Co. Inc. Revenue Share, by Region, 2016
Figure 93 : Novartis AG Revenue Share, by Region, 2016
Figure 94 : Novartis AG Revenue Share, by Business Segment, 2016
Figure 95 : Pfizer Inc. Revenue Share, by Region, 2016
Figure 96 : Pfizer Inc. Revenue Share, by Business Segment, 2016
Figure 97 : Sanofi Revenue Share, by Region, 2016
Figure 98 : Sanofi Revenue Share, by Business Segment, 2016
Figure 99 : Sanofi R&D Expenditure, 2014-2016

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Astrazeneca PLC
  • Boehringer Ingelheim Gmbh
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company LTD.
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Glaxosmithkline PLC
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • United Therapeutics Corp.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll